Feminizing hormone therapy , also known as transfeminine hormone therapy , is hormone therapy and sex reassignment therapy to change the secondary sexual characteristics of transgender people from masculine or androgynous to feminine. Some intersex people also take this form of therapy, according to their personal needs and preferences. The purpose of the therapy is to cause the development of the secondary sex characteristics of the desired sex , such as breasts and a feminine pattern of hair , fat , and muscle distribution. It cannot undo many of the changes produced by naturally occurring puberty , which may necessitate surgery and other treatments to reverse see below. The medications used for feminizing hormone therapy include estrogens , antiandrogens , progestogens , and gonadotropin-releasing hormone modulators GnRH modulators. While the therapy cannot undo the effects of a person's first puberty if it has occurred , developing secondary sex characteristics associated with one's gender has been shown to relieve some or all of the distress and discomfort associated with gender dysphoria , and can help the person to "pass" or be seen as their gender.
COVID-19: Advice, updates and vaccine options
Estrogen Hormone Therapy is a possible way to transition from a male to a female. People want the changes from hormone therapy to happen rapidly, but there are some expectations, long-term considerations, medications, and other factors that need to be understood. As Estrogen Hormone Therapy progresses, the skin can become thinner and drier. Pores produce less oil and become smaller. You may notice that you develop cuts or bruises more often and the odor from your urine and sweat change.
Try out PMC Labs and tell us what you think. Learn More. This study seeks to evaluate the long-term effects of pharmacologic therapy on the bone markers and bone mineral density of transgender patients and to provide a basis for understanding its potential implications on therapies involving implant procedures. Transgender demographics, time under treatment, and treatment received were recorded. The considerable variability between studies did not allow a meta-analysis. All the studies were completed in European countries. Transwomen men to female were more frequent than transmen female to male. Calcium, phosphate, alkaline phosphatase, and osteocalcin levels remained stable. Finally, reduced BMD was observed in transwomen patients receiving long-term cross-sex pharmacotherapy. Considering the limitations of this systematic review, it was concluded that long-term cross-sex pharmacotherapy for transwomen and transmen transgender patients does not alter the calcium, phosphate, alkaline phosphatase, and osteocalcin levels, and will slightly increase the bone formation in both transwomen and transmen patients.
Objective : Sex hormones are not only involved in the formation of reproductive organs, but also induce sexually-dimorphic brain development and organization. Cross-sex hormone administration to transsexuals provides a unique possibility to study the effects of sex steroids on brain morphology in young adulthood. Conclusions : The findings suggest that, throughout life, gonadal hormones remain essential for maintaining aspects of sex-specific differences in the human brain. Transsexualism is the condition in which a person with apparently normal somatic sexual differentiation of one sex is convinced that he or she is actually a member of the opposite sex. This sense is so pronounced and persistent that transsexuals seek treatment to, as far as medically possible, physically change their bodies from male into female or vice versa. Prior to surgical sex reassignment, transsexuals receive treatment with cross-sex hormones. Male-to-female transsexuals MFs are treated with estrogens and anti-androgens to suppress the production and biological effects of circulating androgens and female-to-male transsexuals FMs are treated with androgens in FMs, androgens, without additional hormone treatment, usually suppress menstruation; circulating estrogens are not substantially reduced as a result of peripheral aromatization of administered androgens. There is no known fundamental difference in sensitivity to the biological action of sex steroids on the basis of genetic configurations or gonadal status.